4.6 Review

Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders

Journal

CURRENT MEDICINAL CHEMISTRY
Volume 24, Issue 35, Pages 3851-3878

Publisher

BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/0929867324666170718105557

Keywords

Melatonin; Alzheimer's disease; Parkinson's disease; multiple sclerosis; amyotrophic lateral sclerosis; Huntington's disease; autism spectrum disorders; attention-deficit hyperactivity disorder; headaches; epilepsy; spinal cord injury; ischemic stroke; sleep disorders

Funding

  1. Jerome Lejeune Foundation
  2. Spanish Ministry of Economy and Competitiveness (AEI/FEDER, EU) [PSI2016-76194-R]

Ask authors/readers for more resources

Background: Melatonin is a molecule with numerous properties applicable to the treatment of neurological diseases. Among these properties are the following: potent scavenger of oxygen and nitrogen reactive species, anti-inflammatory features, immuno-enhancing nature, and modulation of circadian rhythmicity. Furthermore, low concentrations of melatonin are usually found in patients with neurological diseases and mental disorders. The positive results obtained in experimental models of diverse pathologies, including diseases of the nervous system (e.g., Alzheimer's disease, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis, Huntington's disease, epilepsy, headaches, etc.) as well as mental and behavioural disordes (e.g., autism spectrum disorders, attention-deficit hyperactivity disorders, etc.), have served as a basis for the design of clinical trials to study melatonin's possible usefulness in human pathology, although the satisfactory results obtained from the laboratory bench are not always applicable to the patient's bedside. Objective: In this article, we review those papers describing the results of the administration of melatonin to humans for various therapeutic purposes in the field of neuropathology. Conclusion: Clinical trials with strong methodologies and appropriate doses of melatonin are necessary to support or reject the usefulness of melatonin in neurological diseases.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available